SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study
- PMID: 35345417
- PMCID: PMC8942480
- DOI: 10.1016/S2666-5247(22)00036-2
SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study
Abstract
Background: The memory immune response is crucial for preventing reinfection or reducing disease severity. However, the robustness and functionality of the humoral and T-cell response to SARS-CoV-2 remains unknown 12 months after initial infection. The aim of this study is to investigate the durability and functionality of the humoral and T-cell response to the original SARS-CoV-2 strain and variants in recovered patients 12 months after infection.
Methods: In this longitudinal cohort study, we recruited participants who had recovered from COVID-19 and who were discharged from the Wuhan Research Center for Communicable Disease Diagnosis and Treatment at the Chinese Academy of Medical Sciences, Wuhan, China, between Jan 7 and May 29, 2020. Patients received a follow-up visit between Dec 16, 2020, and Jan 27, 2021. We evaluated the presence of IgM, IgA, and IgG antibodies against the SARS-CoV-2 nucleoprotein, Spike protein, and the receptor-binding domain 12 months after initial infection, using ELISA. Neutralising antibodies against the original SARS-CoV-2 strain, and the D614G, beta (B.1.351), and delta (B.1.617.2) variants were analysed using a microneutralisation assay in a subset of plasma samples. We analysed the magnitude and breadth of the SARS-CoV-2-specific memory T-cell responses using the interferon γ (IFNγ) enzyme-linked immune absorbent spot (ELISpot) assay and intracellular cytokine staining (ICS) assay. The antibody response and T-cell response (ie, IFN-γ, interleukin-2 [IL-2], and tumour necrosis factor α [TNFα]) were analysed by age and disease severity. Antibody titres were also analysed according to sequelae symptoms.
Findings: We enrolled 1096 patients, including 289 (26·4%) patients with moderate initial disease, 734 (67·0%) with severe initial disease, and 73 (6·7%) with critical initial disease. Paired plasma samples were collected from 141 patients during the follow-up visits for the microneutralisation assay. PBMCs were collected from 92 of 141 individuals at the 12-month follow-up visit, of which 80 were analysed by ELISpot and 92 by ICS assay to detect the SARS-CoV-2-specific memory T-cell responses. N-IgG (899 [82·0%]), S-IgG (1043 [95·2%]), RBD-IgG (1032 [94·2%]), and neutralising (115 [81·6%] of 141) antibodies were detectable 12 months after initial infection in most individuals. Neutralising antibodies remained stable 6 and 12 months after initial infection in most individuals younger than 60 years. Multifunctional T-cell responses were detected for all SARS-CoV-2 viral proteins tested. There was no difference in the magnitude of T-cell responses or cytokine profiles in individuals with different symptom severity. Moreover, we evaluated both antibody and T-cell responses to the D614G, beta, and delta viral strains. The degree of reduced in-vitro neutralising antibody responses to the D614G and delta variants, but not to the beta variant, was associated with the neutralising antibody titres after SARS-CoV-2 infection. We also found poor neutralising antibody responses to the beta variant; 83 (72·2%) of 115 patients showed no response at all. Moreover, the neutralising antibody titre reduction of the recovered patient plasma against the delta variant was similar to that of the D614G variant and lower than that of the beta variant. By contrast, T-cell responses were cross-reactive to the beta variant in most individuals. Importantly, T-cell responses could be detected in all individuals who had lost the neutralising antibody response to SARS-CoV-2 12 months after the initial infection.
Interpretation: SARS-CoV-2-specific neutralising antibody and T-cell responses were retained 12 months after initial infection. Neutralising antibodies to the D614G, beta, and delta viral strains were reduced compared with those for the original strain, and were diminished in general. Memory T-cell responses to the original strain were not disrupted by new variants. This study suggests that cross-reactive SARS-CoV-2-specific T-cell responses could be particularly important in the protection against severe disease caused by variants of concern whereas neutralising antibody responses seem to reduce over time.
Funding: Chinese Academy of Medical Sciences, National Natural Science Foundation, and UK Medical Research Council.
© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.
Conflict of interest statement
We declare no competing interests.
Figures
Similar articles
-
Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: a longitudinal cohort study.Lancet Microbe. 2024 Jan;5(1):e24-e33. doi: 10.1016/S2666-5247(23)00255-0. Epub 2023 Dec 1. Lancet Microbe. 2024. PMID: 38048805 Free PMC article.
-
Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.1.529): a prospective cohort study from Shenzhen, China.Lancet Microbe. 2023 Aug;4(8):e632-e641. doi: 10.1016/S2666-5247(23)00139-8. Epub 2023 Jul 14. Lancet Microbe. 2023. PMID: 37459867 Review.
-
Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study.Lancet Microbe. 2023 May;4(5):e309-e318. doi: 10.1016/S2666-5247(23)00012-5. Epub 2023 Mar 21. Lancet Microbe. 2023. PMID: 36963419 Free PMC article.
-
Defending against SARS-CoV-2: The T cell perspective.Front Immunol. 2023 Jan 27;14:1107803. doi: 10.3389/fimmu.2023.1107803. eCollection 2023. Front Immunol. 2023. PMID: 36776863 Free PMC article. Review.
-
Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.Lancet. 2021 Mar 20;397(10279):1075-1084. doi: 10.1016/S0140-6736(21)00238-5. Lancet. 2021. PMID: 33743869 Free PMC article.
Cited by
-
Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes.Viruses. 2024 Apr 26;16(5):685. doi: 10.3390/v16050685. Viruses. 2024. PMID: 38793566 Free PMC article. Review.
-
Longitudinal Dynamics of Immune Response in Occupational Populations Post COVID-19 Infection in the Changning District of Shanghai, China.Viruses. 2024 Apr 25;16(5):672. doi: 10.3390/v16050672. Viruses. 2024. PMID: 38793554 Free PMC article.
-
The impact of SARS-CoV-2 spike mutation on peptide presentation is HLA allomorph-specific.Curr Res Struct Biol. 2024 Apr 29;7:100148. doi: 10.1016/j.crstbi.2024.100148. eCollection 2024. Curr Res Struct Biol. 2024. PMID: 38742159 Free PMC article.
-
Immune Response to an Inactivated Vaccine of SARS-CoV-2 (CoronaVac) in an Indigenous Brazilian Population: A Cohort Study.Vaccines (Basel). 2024 Apr 10;12(4):402. doi: 10.3390/vaccines12040402. Vaccines (Basel). 2024. PMID: 38675784 Free PMC article.
-
Immune Responses in Discharged COVID-19 Patients With and Without Long COVID Symptoms.Open Forum Infect Dis. 2024 Apr 1;11(4):ofae137. doi: 10.1093/ofid/ofae137. eCollection 2024 Apr. Open Forum Infect Dis. 2024. PMID: 38577029 Free PMC article.
References
-
- Karlsson AC, Humbert M, Buggert M. The known unknowns of T cell immunity to COVID-19. Sci Immunol. 2020;5 - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous